Talazoparib Improves Overall Survival in Metastatic CRPC

(MedPage Today) -- An analysis of a phase III trial presented at this year's American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium showed that adding the PARP inhibitor talazoparib (Talzenna) to enzalutamide (Xtandi) significantly...